YM-348 je lek sa indazolnim osnovom koji deluje kao potentan i selektivan agonist5-HT2Creceptor, sa EC50 vrednošću od 1 nM i 15x selektivnošću u odnosu na 5-HT2A. On je umereno selektivan 3x u odnosu na blisko srodni 5-HT2B receptor.[1][2] On ispoljava termogeno i anoreksično dejsto u životinjskim studijama, što ga čini potencijalno korisnim u lečenju gojaznosti.[3][4][5][6]
↑Kimura,Y;Hatanaka,K;Naitou,Y;Maeno,K;Shimada,I;Koakutsu,A;Wanibuchi,F;Yamaguchi,T(2004).„Pharmacological profile of YM348, a novel, potent and orally active 5-HT2C receptor agonist”.European journal of pharmacology483(1): 37–43.PMID14709324.
↑Shimada,I;Maeno,K;Kazuta,K;Kubota,H;Kimizuka,T;Kimura,Y;Hatanaka,K;Naitou,Yi dr..(2008).„Synthesis and structure-activity relationships of a series of substituted 2-(1H-furo2,3-gindazol-1-yl)ethylamine derivatives as 5-HT2C receptor agonists”.Bioorganic & medicinal chemistry16(4): 1966–82.DOI:10.1016/j.bmc.2007.10.100.PMID18035544.
↑Hayashi A, Sonoda R, Kimura Y, Takasu T, Suzuki M, Sasamata M, Miyata K(2004).„Antiobesity effect of YM348, a novel 5-HT2C receptor agonist, in Zucker rats”.Brain research1011(2): 221–7.DOI:10.1016/j.brainres.2004.03.032.PMID15157808.
↑Smith,BM;Thomsen,WJ;Grottick,AJ(2006).„The potential use of selective 5-HT2C agonists in treating obesity”.Expert opinion on investigational drugs15(3): 257–66.DOI:10.1517/13543784.15.3.257.PMID16503763.
↑Nilsson,BM(2006).„5-Hydroxytryptamine 2C (5-HT2C) receptor agonists as potential antiobesity agents”.Journal of medicinal chemistry49(14): 4023–34.DOI:10.1021/jm058240i.PMID16821762.
↑Wacker,DA;Miller,KJ(2008).„Agonists of the serotonin 5-HT2C receptor: preclinical and clinical progression in multiple diseases”.Current opinion in drug discovery & development11(4): 438–45.PMID18600561.